Abstract:Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). In the global Phase 3 ORAL Sync study (NCT00856544), tofacitinib improved disease activity in patients (pts) who had active RA despite treatment with nonbiologic disease-modifying antirheumatic drugs (DMARDs).1 Objectives To report a post-hoc analysis of efficacy and safety in a subgroup of Chinese pts. Methods ORAL Sync was a 1-year, double-blind, placebo-controlled, parallel-group study. Pts (N=795) with active RA were randomised 4:4:1:1 to oral tofacitinib 5 or 10 mg twice daily (BID), or placebo advanced to tofacitinib 5 or 10 mg BID at 3 (nonresponders) or 6 (remaining pts) months. All pts remained on ≥1 background nonbiologic DMARD throughout. Co-primary efficacy endpoints were ACR20 response rate at Month 6 (M6), change from baseline in physical function (HAQ-DI) at M3, and proportion of pts achieving DAS28-4(ESR)<2.6 at M6. Efficacy and safety outcomes in the subgroup of pts from 20 centres in China vs the global study population are reported; post-hoc tests for statistical significance were performed. Results In total, 792 pts were treated (global population), including 216 Chinese pts. Baseline demographics were similar across treatment groups in the Chinese population (n=86 tofacitinib 5 mg BID; n=86 tofacitinib 10 mg BID; n=44 placebo; 85% female; mean age, 48 years). Both tofacitinib doses demonstrated significant improvements vs placebo in ACR20 response rate at M6 in Chinese pts (p≤0.0001). ACR20 response rates at M6 were numerically higher with tofacitinib in Chinese pts vs the global population (Table). Numerically more Chinese pts achieved DAS28-4(ESR)<2.6 with tofacitinib 5 and 10 mg BID vs placebo at M6, which was significant with the 10 mg BID dose (p=0.1803 and p=0.0120 with tofacitinib 5 and 10 mg BID, respectively; Table). Both tofacitinib doses also demonstrated significant improvements in HAQ-DI at M3 in Chinese pts; least squares (LS) mean difference (95% CI) vs placebo was -0.23 (-0.40, -0.05; p=0.0137) and -0.35 (-0.53, -0.17; p=0.0002) with tofacitinib 5 and 10 mg BID, respectively. Tofacitinib efficacy was generally sustained over 12 months. The most frequently reported adverse events (AEs) were upper respiratory tract infection, elevated aminotransferases, and leukopenia. Incidence of AEs, serious AEs (SAEs), AE discontinuations, serious infections and herpes zoster infections over M0–3 are reported in the Table. SAEs over M3–6 and after M6 were reported in 2 (1.2%) Chinese pt with tofacitinib 10 mg BID. Conclusions Tofacitinib, in combination with background DMARDs, significantly improved signs and symptoms and improved physical function vs placebo over 1 year in Chinese pts with active RA. Efficacy and safety findings in the Chinese subgroup were consistent with the global population. References Kremer J et al. Ann Intern Med 2013; 159: 253-261. Acknowledgements All aspects of this work were funded by Pfizer Inc. Editorial support, under the direction of the authors, was provided by Amanda Pedder of Complete Medical Communications, and funded by Pfizer Inc. Disclosure of Interest Y. An: None declared, Z. Li: None declared, Q. Wu Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, K. Kwok Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, L. Wang Shareholder of: Pfizer Inc, Employee of: Pfizer Inc

Neutrophil-lymphocyte ratio: an independent predictor of the herpes zoster risk in rheumatoid arthritis patients treated with tofacitinib

[Neutrophil-lymphocyte and platelet-lymphocyte ratios for assessing disease activity in patients with rheumatoid arthritis receiving tofacitinib treatment].

Increased risk of herpes zoster with tofacitinib treatment in Korean patients with rheumatoid arthritis: a single-center prospective study

Real-world risk factors for herpes zoster in patients with rheumatoid arthritis undergoing tofacitinib treatment

Tuberculosis, Hepatitis B and Herpes Zoster in Tofacitinib-Treated Patients with Rheumatoid Arthritis

Neutrophil-to-lymphocyte ratio as a predictive biomarker for hyperprogressive disease mediated by immune checkpoint inhibitors: a systematic review and meta-analysis

Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

The value of the neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio as complementary diagnostic tools in the diagnosis of rheumatoid arthritis: A multicenter retrospective study

Neutrophil-to-lymphocyte Ratio: an Effective Predictor of Corticosteroid Response in IgA Nephropathy

CD4/CD8 Ratio: an Independent Predictor of Herpes Zoster in Patients with Autoimmune Inflammatory Rheumatic Diseases

Increased Risk of Herpes Zoster in Rheumatoid Arthritis Not Only Due to JAK Inhibitors—Study of 392 Patients from Single University Center

AB0321 Negative correlation of the absolute number of cd4 +cd25+foxp3+regulatory t cells to the levels of rheumatoid factor in peripheral blood of new onset patients with rheumatoid arthritis

Association of Blood Neutrophil-Lymphocyte Ratio with Short-Term Prognosis and Severity of Tuberculosis Meningitis Patients Without HIV Infection.

Anti-peptide antibodies, anti-SNRK and anti-HUWE1 antibodies, as potential predictors of good response to tofacitinib therapy in rheumatoid arthritis patients

Role of Platelet/Lymphocyte, Neutrophil/Lymphocyte, and Interleukin-37/Interleukin-17 Ratios in the Occurrence and Treatment of Rheumatoid Arthritis

Association between the neutrophil-to-lymphocyte ratio and psoriasis: a cross-sectional study of the National Health and Nutrition Examination Survey 2011-2014

Optimal timing of recombinant herpes zoster virus vaccination for a JAK inhibitor treatment in rheumatoid arthritis: a multicentre, open-label, randomised comparative study (STOP-HZ study): study protocol

Platelet/Lymphocyte, Lymphocyte/Monocyte, and Neutrophil/Lymphocyte Ratios As Biomarkers in Patients with Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung Disease.

AB0514 Efficacy and Safety of Tofacitinib in Chinese Patients with Active Rheumatoid Arthritis: Subgroup Analysis from a Phase 3 Study of Tofacitinib in Combination with Nonbiologic Disease-Modifying Antirheumatic Drugs

Tumor Necrosis Factor Alpha -308G/A Gene Polymorphisms Combined with Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio Predicts the Efficacy and Safety of Anti-TNF-α Therapy in Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Arthritis

Diagnostic accuracy of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in rheumatoid arthritis: a systematic review and meta-analysis